45 CFR § 180 compliance
B · 85
This hospital published most of what § 180 requires.
●Machine-readable file published
●Gross / standard charges
●Discounted cash price
●Payer-specific negotiated rates
○Min / max negotiated charges
●Free, public, no login required
Procedures listed
176,338
Insurances with rates
13
CPT / HCPCS codes
0
Source MRF
Most expensive procedures (gross)
51905029-4124794
$82,855
30237-8900-06 - sipuleucel-T - Susp
Gross
$212,448
51905029-4124794
$44,614
30237-8900-06 - sipuleucel-T - Susp
Gross
$212,448
102534551-4119659
$76,050
71336-1001-01 - givosiran 189 mg/mL Soln
Gross
$195,000
102534551-4119659
$40,950
71336-1001-01 - givosiran 189 mg/mL Soln
Gross
$195,000
103958918-4124798
$74,850
69866-1030-05 - autologous cultured chondrocytes 1
Gross
$191,923
103958918-4124798
$40,304
69866-1030-05 - autologous cultured chondrocytes 1
Gross
$191,923
103958919-4124798
$74,850
69866-1030-08 - autologous cultured chondrocytes 1
Gross
$191,923
103958919-4124798
$40,304
69866-1030-08 - autologous cultured chondrocytes 1
Gross
$191,923
1279402-4119659
$68,412
00003-2328-22 - ipilimumab Soln
Gross
$175,416
1279402-4119659
$36,837
00003-2328-22 - ipilimumab Soln
Gross
$175,416
1286149-4119659
$55,753
54396-0801-01 - pegloticase Soln
Gross
$142,958
1286149-4119659
$30,021
54396-0801-01 - pegloticase Soln
Gross
$142,958
95367892-4119659
$55,753
60809-0801-01 - pegloticase 8 mg/mL Soln
Gross
$142,958
95367892-4119659
$30,021
60809-0801-01 - pegloticase 8 mg/mL Soln
Gross
$142,958
94990000-4119659
$50,547
57894-0061-03 - ustekinumab 90 mg/mL Soln
Gross
$129,608
94990000-4119659
$27,218
57894-0061-03 - ustekinumab 90 mg/mL Soln
Gross
$129,608
127260891-4496069
$50,159
S-INS-REP PACE-DEFIB[NMRO]
Gross
$128,612
127260891-4496069
$27,009
S-INS-REP PACE-DEFIB[NMRO]
Gross
$128,612
1282361-4119659
$49,800
57665-0002-02 - pegaspargase 3750. Soln
Gross
$127,691
1282361-4119659
$26,815
57665-0002-02 - pegaspargase 3750. Soln
Gross
$127,691
1282362-4119659
$49,800
54482-0301-01 - pegaspargase 3750. Soln
Gross
$127,691
1282362-4119659
$26,815
54482-0301-01 - pegaspargase 3750. Soln
Gross
$127,691
99090561-4119659
$49,800
72694-0954-01 - pegaspargase 3,750 IntlUnit(s) / 5
Gross
$127,691
99090561-4119659
$26,815
72694-0954-01 - pegaspargase 3,750 IntlUnit(s) / 5
Gross
$127,691
102525788-4119659
$45,789
25682-0028-01 - ravulizumab 100 mg/mL Soln
Gross
$117,407
102525788-4119659
$24,655
25682-0028-01 - ravulizumab 100 mg/mL Soln
Gross
$117,407
127538326-4124794
$45,566
00310-4535-30 - tremelimumab actl 20 mg/mL Soln
Gross
$116,836
127538326-4124794
$24,536
00310-4535-30 - tremelimumab actl 20 mg/mL Soln
Gross
$116,836
112512821-4496069
$41,097
S-PER INS LH VAD ART[NMRO]
Gross
$105,376
112512821-4496069
$22,129
S-PER INS LH VAD ART[NMRO]
Gross
$105,376
113233796-4496069
$41,097
S-PER INS RH VAD ART[NMRO]
Gross
$105,376
113233796-4496069
$22,129
S-PER INS RH VAD ART[NMRO]
Gross
$105,376
134322469-4119664
$37,617
99999-1029-52 - skin substitute 50.27 cm2 Misc
Gross
$96,453
134322469-4119664
$20,255
99999-1029-52 - skin substitute 50.27 cm2 Misc
Gross
$96,453
101891901-4124794
$37,615
72187-0401-01 - tagraxofusp 1000 mcg/mL Soln
Gross
$96,448
101891901-4124794
$20,254
72187-0401-01 - tagraxofusp 1000 mcg/mL Soln
Gross
$96,448
114133592-4496069
$37,206
MEDT-VLV AOR EVOLUT R PRCN 26[NMRO]
Gross
$95,399
114133592-4496069
$20,034
MEDT-VLV AOR EVOLUT R PRCN 26[NMRO]
Gross
$95,399
114133596-4496069
$37,206
MEDT-VLV AOR EVOLUT R PRCN 29[NMRO]
Gross
$95,399
114133596-4496069
$20,034
MEDT-VLV AOR EVOLUT R PRCN 29[NMRO]
Gross
$95,399
114133701-4496069
$37,206
MEDT-VLV AOR EVOLUT R PRCN 23[NMRO]
Gross
$95,399
114133701-4496069
$20,034
MEDT-VLV AOR EVOLUT R PRCN 23[NMRO]
Gross
$95,399
114133702-4496069
$37,206
MEDT-VLV AOR EVOLUT R 34[NMRO]
Gross
$95,399
114133702-4496069
$20,034
MEDT-VLV AOR EVOLUT R 34[NMRO]
Gross
$95,399
114133901-4496069
$37,206
MEDT-VLV AOR EVOLUT PRO 29[NMRO]
Gross
$95,399
114133901-4496069
$20,034
MEDT-VLV AOR EVOLUT PRO 29[NMRO]
Gross
$95,399
114134068-4496069
$37,206
MEDT-VLV AOR EVOLUT PRO 26[NMRO]
Gross
$95,399
114134068-4496069
$20,034
MEDT-VLV AOR EVOLUT PRO 26[NMRO]
Gross
$95,399
114134069-4496069
$37,206
MEDT-VLV AOR EVOLUT PRO 23[NMRO]
Gross
$95,399
114134069-4496069
$20,034
MEDT-VLV AOR EVOLUT PRO 23[NMRO]
Gross
$95,399
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| 51905029-4124794 | 30237-8900-06 - sipuleucel-T - Susp | $212,448 | $82,855 | — | — | 5 |
| 51905029-4124794 | 30237-8900-06 - sipuleucel-T - Susp | $212,448 | $44,614 | — | — | 7 |
| 102534551-4119659 | 71336-1001-01 - givosiran 189 mg/mL Soln | $195,000 | $76,050 | — | — | 5 |
| 102534551-4119659 | 71336-1001-01 - givosiran 189 mg/mL Soln | $195,000 | $40,950 | — | — | 7 |
| 103958918-4124798 | 69866-1030-05 - autologous cultured chondrocytes 1 | $191,923 | $74,850 | — | — | 5 |
| 103958918-4124798 | 69866-1030-05 - autologous cultured chondrocytes 1 | $191,923 | $40,304 | — | — | 7 |
| 103958919-4124798 | 69866-1030-08 - autologous cultured chondrocytes 1 | $191,923 | $74,850 | — | — | 5 |
| 103958919-4124798 | 69866-1030-08 - autologous cultured chondrocytes 1 | $191,923 | $40,304 | — | — | 7 |
| 1279402-4119659 | 00003-2328-22 - ipilimumab Soln | $175,416 | $68,412 | — | — | 5 |
| 1279402-4119659 | 00003-2328-22 - ipilimumab Soln | $175,416 | $36,837 | — | — | 7 |
| 1286149-4119659 | 54396-0801-01 - pegloticase Soln | $142,958 | $55,753 | — | — | 5 |
| 1286149-4119659 | 54396-0801-01 - pegloticase Soln | $142,958 | $30,021 | — | — | 7 |
| 95367892-4119659 | 60809-0801-01 - pegloticase 8 mg/mL Soln | $142,958 | $55,753 | — | — | 5 |
| 95367892-4119659 | 60809-0801-01 - pegloticase 8 mg/mL Soln | $142,958 | $30,021 | — | — | 7 |
| 94990000-4119659 | 57894-0061-03 - ustekinumab 90 mg/mL Soln | $129,608 | $50,547 | — | — | 5 |
| 94990000-4119659 | 57894-0061-03 - ustekinumab 90 mg/mL Soln | $129,608 | $27,218 | — | — | 7 |
| 127260891-4496069 | S-INS-REP PACE-DEFIB[NMRO] | $128,612 | $50,159 | — | — | 5 |
| 127260891-4496069 | S-INS-REP PACE-DEFIB[NMRO] | $128,612 | $27,009 | — | — | 7 |
| 1282361-4119659 | 57665-0002-02 - pegaspargase 3750. Soln | $127,691 | $49,800 | — | — | 5 |
| 1282361-4119659 | 57665-0002-02 - pegaspargase 3750. Soln | $127,691 | $26,815 | — | — | 7 |
| 1282362-4119659 | 54482-0301-01 - pegaspargase 3750. Soln | $127,691 | $49,800 | — | — | 5 |
| 1282362-4119659 | 54482-0301-01 - pegaspargase 3750. Soln | $127,691 | $26,815 | — | — | 7 |
| 99090561-4119659 | 72694-0954-01 - pegaspargase 3,750 IntlUnit(s) / 5 | $127,691 | $49,800 | — | — | 5 |
| 99090561-4119659 | 72694-0954-01 - pegaspargase 3,750 IntlUnit(s) / 5 | $127,691 | $26,815 | — | — | 7 |
| 102525788-4119659 | 25682-0028-01 - ravulizumab 100 mg/mL Soln | $117,407 | $45,789 | — | — | 5 |
| 102525788-4119659 | 25682-0028-01 - ravulizumab 100 mg/mL Soln | $117,407 | $24,655 | — | — | 7 |
| 127538326-4124794 | 00310-4535-30 - tremelimumab actl 20 mg/mL Soln | $116,836 | $45,566 | — | — | 5 |
| 127538326-4124794 | 00310-4535-30 - tremelimumab actl 20 mg/mL Soln | $116,836 | $24,536 | — | — | 7 |
| 112512821-4496069 | S-PER INS LH VAD ART[NMRO] | $105,376 | $41,097 | — | — | 5 |
| 112512821-4496069 | S-PER INS LH VAD ART[NMRO] | $105,376 | $22,129 | — | — | 7 |
| 113233796-4496069 | S-PER INS RH VAD ART[NMRO] | $105,376 | $41,097 | — | — | 5 |
| 113233796-4496069 | S-PER INS RH VAD ART[NMRO] | $105,376 | $22,129 | — | — | 7 |
| 134322469-4119664 | 99999-1029-52 - skin substitute 50.27 cm2 Misc | $96,453 | $37,617 | — | — | 5 |
| 134322469-4119664 | 99999-1029-52 - skin substitute 50.27 cm2 Misc | $96,453 | $20,255 | — | — | 7 |
| 101891901-4124794 | 72187-0401-01 - tagraxofusp 1000 mcg/mL Soln | $96,448 | $37,615 | — | — | 5 |
| 101891901-4124794 | 72187-0401-01 - tagraxofusp 1000 mcg/mL Soln | $96,448 | $20,254 | — | — | 7 |
| 114133592-4496069 | MEDT-VLV AOR EVOLUT R PRCN 26[NMRO] | $95,399 | $37,206 | — | — | 6 |
| 114133592-4496069 | MEDT-VLV AOR EVOLUT R PRCN 26[NMRO] | $95,399 | $20,034 | — | — | 7 |
| 114133596-4496069 | MEDT-VLV AOR EVOLUT R PRCN 29[NMRO] | $95,399 | $37,206 | — | — | 6 |
| 114133596-4496069 | MEDT-VLV AOR EVOLUT R PRCN 29[NMRO] | $95,399 | $20,034 | — | — | 7 |
| 114133701-4496069 | MEDT-VLV AOR EVOLUT R PRCN 23[NMRO] | $95,399 | $37,206 | — | — | 6 |
| 114133701-4496069 | MEDT-VLV AOR EVOLUT R PRCN 23[NMRO] | $95,399 | $20,034 | — | — | 7 |
| 114133702-4496069 | MEDT-VLV AOR EVOLUT R 34[NMRO] | $95,399 | $37,206 | — | — | 6 |
| 114133702-4496069 | MEDT-VLV AOR EVOLUT R 34[NMRO] | $95,399 | $20,034 | — | — | 7 |
| 114133901-4496069 | MEDT-VLV AOR EVOLUT PRO 29[NMRO] | $95,399 | $37,206 | — | — | 6 |
| 114133901-4496069 | MEDT-VLV AOR EVOLUT PRO 29[NMRO] | $95,399 | $20,034 | — | — | 7 |
| 114134068-4496069 | MEDT-VLV AOR EVOLUT PRO 26[NMRO] | $95,399 | $37,206 | — | — | 6 |
| 114134068-4496069 | MEDT-VLV AOR EVOLUT PRO 26[NMRO] | $95,399 | $20,034 | — | — | 7 |
| 114134069-4496069 | MEDT-VLV AOR EVOLUT PRO 23[NMRO] | $95,399 | $37,206 | — | — | 6 |
| 114134069-4496069 | MEDT-VLV AOR EVOLUT PRO 23[NMRO] | $95,399 | $20,034 | — | — | 7 |
Showing top 50 of 176,338 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.